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Abstract We evaluated the presentation, treatment, and outcome of infants who present with ventricular
tachycardia in the first year of life. Seventy-six infants were admitted to our institution with a diagnosis
of ventricular tachycardia between January, 1987 and May, 2006. Forty-five infants were excluded from
the study because of additional confounding diagnoses including accelerated idioventricular rhythm, Wolff–
Parkinson–White syndrome, supraventricular tachycardia with aberrancy, long QT syndrome, cardiac
rhabdomyoma, myocarditis, congenital lesions, or incomplete data. The remaining 31 included infants who
had a median age at presentation of 1 day, with a range from 1 to 255 days, and a mean ventricular tachycardia
rate of 213 beats per minute, with a range from 171 to 280, at presentation. The infants were treated
chronically with propranolol (38.7%), amiodarone (12.9%), mexiletine (3.2%), propranolol and mexiletine
(9.7%), or propranolol and procainamide (6.5%). The median duration of treatment was 13 months, with a
range from 3 to 105 months. Ventricular tachycardia resolved spontaneously in all infants. No patient died, or
received catheter ablation or device therapy. Median age at last ventricular tachycardia was 59 days, with a
range from 1 to 836 days. Mean follow-up was 45 months, with a range from 5 to 164 months, with a mean
ventricular tachycardia-free period of 40 months. Infants with asymptomatic ventricular tachycardia, a
structurally normal heart, and no additional electrophysiological diagnosis all had spontaneous resolution of
tachycardia. Furthermore, log-rank analysis of the time to ventricular tachycardia resolution showed no
difference between children who received chronic outpatient anti-arrhythmic treatment and those who had no
such therapy. While indications for therapy cannot be determined from this study, lack of symptoms or
myocardial dysfunction suggests that therapy may not be necessary.
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I
DIOPATHIC VENTRICULAR TACHYCARDIA IN CHILDREN
with structurally normal heart was first published
in 1942 (Rosenbaum, American journal of Diseases
in Children). Since that time, there have been several
reports of idiopathic ventricular tachycardia in
children with structurally normal heart, which
suggest that this disease follows a benign, self-
limited course.1–8 However, others have suggested
that idiopathic ventricular tachycardia could result in
death.9,10 As such, treatment recommendations vary
from conservative observation to medical therapy,
radiofrequency catheter ablation, or even invasive
surgical procedures.1,2,3,8,9,11–13 The objective of this
Correspondence to: L. A. Rhodes, MD, Division of Cardiology, Department of
Pediatrics, West Virginia University School of Medicine, 1 Medical Center
Drive, Morgantown, West Virginia 26506, United States of America. Tel: 304
293 7036; Fax: 304 293 1409; E-mail: larhodes@hsc.wvu.edu
study was to evaluate the presentation, treatment,
and outcome of infants who present with ventricular
tachycardia and structurally normal heart in the first
year of life. We hypothesised that patient and
diagnostic data including demographics, symptoma-
tology, initial electrocardiogram, 24-hour Holter
monitor, and echocardiogram data may predict a
benign and self-limited process in some infants with
ventricular tachycardia. We also sought to identify
the relationship between the initial clinical hospital
course and the time to ventricular tachycardia
resolution. We hypothesised that a more recalcitrant
ventricular tachycardia upon initial presentation may
portend a more difficult or prolonged long-term
clinical course.
This report describes the largest cohort of
infants from a single centre in which children with
ventricular tachycardia presented in the first year of
life. Furthermore, it provides the first data that anti-
arrhythmic medications do not hasten the resolution
of a discrete population of infants with ventricular
tachycardia. Ideally, a randomised trial would be
performed to determine the efficacy of medications in
the treatment of such a disease. However, given the
incidence of this disease process, such a study is
not possible at this time. As an alternative, we hope
this report provides some evidence that there is a
role for withholding anti-arrhythmic medications in
a discrete population of infants with ventricular
tachycardia and structurally normal heart.
Methods
Study design
We performed a single-centre retrospective analysis
of infants and infants with an admission diagnosis
of ventricular tachycardia to our institution between
January, 1987 and May, 2006. The Institutional
Review Board at The Children’s Hospital of
Philadelphia approved this study. Patient charts
were reviewed for demographic information, pre-
senting symptoms, electrocardiogram, 24-hour
Holter monitor, echocardiogram data, birth and
family history, pre-hospital and inpatient therapy,
and outpatient medications. Length of hospital stay
and the number of inpatient medication changes
were noted. Follow-up data included duration of
follow-up, symptoms, and outpatient medications.
Follow-up Holter monitoring was reviewed for
the frequency of premature ventricular contractions,
ventricular couplets, and runs of ventricular tachy-
cardia. Age at most recent ventricular tachycardia
episode, duration of medical therapy, and length of
follow-up were also noted. Occurrence of symptoms
was assessed at each follow-up visit.
Definitions
Ventricular tachycardia was defined as four or more
consecutive wide QRS complexes with atrioventri-
cular dissociation at a rate more than 20% greater
the preceding sinus rhythm. The diagnosis was
confirmed by electrocardiogram, rhythm strip,
or 24-hour Holter monitor recording. Ventricular
arrhythmias at a rate less than 20% greater than the
sinus rhythm, were termed accelerated idioventri-
cular rhythm and were excluded from analysis.
Bundle branch morphology was determined if
ventricular tachycardia was recorded on 12-lead
electrocardiogram.
Initial ventricular tachycardia rate, length of
hospital stay, and the number of drug failures were
used as surrogate markers for disease severity. Such
markers allowed characterisation of the initial clinical
course of the disease. As ventricular tachycardia
resolved without significant morbidity in all infants,
we chose time to ventricular tachycardia resolution as
an indication of the long-term clinical course.
Patient selection
Infants with an admission diagnosis of ventricular
tachycardia, who were under the age of 1 year at the
time of admission were included following a review
of the presenting electrocardiogram or rhythm strip.
Infants were excluded if they had a haemodynamically
significant congenital cardiac disease, cardiomyopa-
thy, cardiac tumour, or were in overt cardiac failure on
admission to the hospital. Furthermore, a diagnosis
of long QT syndrome or Wolff–Parkinson–White
syndrome was also grounds for exclusion. Finally,
infants were excluded if follow-up of at least 6 months
was not available.
Statistical analysis
Statistical analysis was performed using SPSS
(version 11.5; Chicago, Illinois, United States of
America) and GraphPad Prism version 5.0 (Graph-
Pad Software, San Diego, California, United States
of America). Significance was set a priori at p less
than 0.05. Student’s t-test was used to assess the
relationship between continuous variables that were
normally distributed, unless indicated. The Mann–
Whitney test was used to compare the means
of non-normally distributed continuous variables.
Such an analysis was performed to determine
whether a correlation could be made between the
date of clinical presentation and whether the child
was prescribed outpatient medication. Using Excel
(Microsoft 2008), the dates were converted into a
numeric value by calculating the number of days
between a reference day (1 January, 1900) and the
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date of presentation. These numbers were then
entered into Graphpad Prism 5.0, where the
Mann–Whitney analysis was performed and the
data were graphed. Chi-square analysis was used to
determine significance of the categorical data. Linear
regression analysis was used to assess the relationship
between variables and outcome. Kaplan–Meier
survival curves were constructed using the number
of days from the first occurrence of ventricular
tachycardia to the first subsequent Holter study that
showed no evidence of ventricular tachycardia. The
log-rank statistic was used to assess the statistical
significance between the Kaplan–Meier curves. Bar
graphs, linear regression plots, and Kaplan–Meier
survival curves were constructed using GraphPad
Prism version 5.0 for Windows.
Results
Patient characteristics
A summary of the baseline patient characteristics is
presented in Table 1. Seventy-six infants under the
age of 1 year had an admission diagnosis code of
ventricular tachycardia. Infants with the following
were excluded from further analysis: eight infants
with supraventricular tachycardia with aberrancy,
four infants with accelerated idioventricular rhythm,
four infants with Wolff–Parkinson–White syndrome,
three infants with long QT syndrome, three infants
with cardiac rhabdomyoma, two infants with cardio-
myopathy, 21 infants with haemodynamically sig-
nificant congenital lesions, and nine infants whose
length of follow-up was less than 6 months. Thus, 31
infants were included in the study.
Of the 24 infants with a full 12-lead electro-
cardiogram available for review, 20 had left bundle
branch morphology and four had right bundle
branch morphology. Bundle branch morphology
could not be assigned to the remaining seven infants
for whom the 12-lead electrocardiograms could not
be reviewed. Kaplan–Meier survival curves for the
time to arrhythmia resolution according to bundle
branch morphology of the ventricular tachycardia
were drawn. A comparison of these curves by log-
rank statistic showed no significant difference (log-
rank test5 4.196, p5 0.1227).
Symptoms
The majority of the infants had no symptoms at
the time of presentation. Twelve infants presented
during the prenatal period. Often, the diagnosis of
ventricular tachycardia was an incidental finding in
infants being observed for another condition. Such
alternate diagnoses included transient tachypnoea of
the newborn, infant of a diabetic mother, and minor
genitourinary system abnormalities. No infant had
symptoms of cardiovascular compromise, cyanosis,
pallor, or seizure. Four infants had non-cardio-
vascular symptoms at the time of presentation: three
infants had fever and mild tachypnoea without
evidence of feeding intolerance, gallop, or hepato-
megaly; one infant had poor feeding and emesis
without evidence of associated respiratory distress.
Viral titres
Viral titres were sent on all four infants with
symptoms at presentation with no positive results.
The titres were drawn on six additional, asympto-
matic infants. All infants were seronegative.
Electrocardiogram results
A baseline electrocardiogram performed when the
infants were not in tachycardia showed a mean RR
interval of 433 milliseconds, with a standard
deviation of 105 milliseconds, mean PR interval
of 114 milliseconds, with a standard deviation of
5.2 milliseconds, mean corrected QT interval of 405
milliseconds, with a standard deviation of 26.2
milliseconds, and a mean QRS axis of 109 degrees,
Table 1. Patient characteristics.
Characteristics
Median age (days) 1 Range: 1–275
Gender Male: 13 Female: 18
Median maximum VT rate (bpm) 214 Range: 158–300*
Median QRS width in Tachycardia (ms) 100 Range: 80–120
Mean corrected QT interval length on baseline ECG (ms) 4056 26.2 Range: 340–460
VT bundle branch morphology Left: 20; Right: 4 Indeterminate: 7
Symptoms Yes: 4 patients No: 27
Shortening Fraction (%; n5 18) 37.76 7.8 Range: 27–56
Qualitative cardiac function by echocardiogram (number of patients) Normal: 12 Mildly decreased: 1
ECG5 electrocardiogram; VT5 ventricular tachycardia
*Sinus rhythm rate of patient with ventricular tachycardia at a rate of 158 was 122 bpm
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with a standard deviation of 39.1 degrees. Ventricular
premature contractions were noted in 17 of 31 infants
on initial electrocardiogram.
Initial Holter monitor results
Holter monitor recording was performed in all
infants. One infant had no ventricular tachycardia
on their initial Holter monitor study. The mean
maximum heart rate during ventricular tachycardia
was 195 beats per minute, with a standard deviation
of 57.7 beats per minute, whereas the median sinus
heart rates during the entire recording period was
136 beats per minute, with a standard deviation
of 20.9 beats per minute. The median number of
ventricular tachycardia episodes per patient was 717,
with a range from 0 to 77,449, whereas the median
longest run of ventricular tachycardia was 28.5 beats
per minute, with a range from 4 to 12,786.
Echocardiogram results
All infants underwent complete echocardiographic
evaluation. Three infants had haemodynamically
insignificant patent ductus arteriosus. No child had
significant atrioventricular or semilunar valve insuffi-
ciency. A mean shortening fraction of 37.7%, with a
standard deviation of 7.8%, was found in the 18
infants who had a quantitative assessment of cardiac
function. Of the remaining 13 infants, qualitative
assessment revealed one infant with mildly decreased
shortening fraction, whereas the remaining 12 had
normal ventricular shortening.
Medications and interventions
Fifteen infants received intravenous anti-arrhythmic
medications while in the hospital: 13 received
lidocaine, one received amiodarone and one received
esmolol. The oral medications administered to infants
while in the hospital are summarised in Fig 1a.
During the initial hospitalisation, 19 infants had
no anti-arrhythmic drug failures, seven infants had
one failure, three infants had two failures, one infant
had three failures, and one infant had four failures.
Linear regression showed no correlation between
the number of inpatient medications and the
time to freedom from arrhythmia (r5 0.0003985,
p5 0.9166).
In addition to medication administration, other
potential interventions included cardioversion,
transoesophogeal electrophysiology study, invasive
electrophysiology study, radiofrequency catheter
ablation, or surgery. In our cohort, one infant
underwent direct current cardioversion. No infant
underwent radiofrequency catheter ablation or
surgical intervention.
Length of stay
The median length of stay was 7 days, with a range
from 1 to 38 days.
Discharge medication
Outpatient oral anti-arrhythmic medication usage is
summarised in Fig 1b. Nine infants were discharged
home on no anti-arrhythmic drugs. Twenty-two
infants received outpatient medications. Outpatient
oral anti-arrhythmic drugs used included propra-
nolol, procainamide, mexiletine, and amiodarone.
Seven infants were treated with a combination of
medications: five infants were given mexiletine and
propranolol, whereas two infants were treated with
procainamide and propranolol.
Figure 1.
Anti-arrhythmic drug therapy. (a) Inpatient oral anti-arrhythmic
drug usage. The graph depicts the number of infants treated with a
single anti-arrhythmic agent or anti-arrhythmic drug combination;
none5 no inpatient oral anti-arrhythmic therapy; PRP5 propra-
nolol; AMI5 amiodarone; MEX5mexiletine; PRC5 procaina-
mide. (b) Outpatient oral anti-arrhythmic drug usage. The graph
depicts the number of infants treated with a single anti-arrhythmic
agent or anti-arrhythmic drug combination; none5 no outpatient
oral anti-arrhythmic therapy; PRP5 propranolol; MEX5mex-
iletine; AMI5 amiodarone; PRC5 procainamide.
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An analysis to assess the differences between the
group that received outpatient anti-arrhythmic
drugs and those who received no outpatient anti-
arrhythmic drugs failed to detect any statistically
significant association. The results of this analysis
are summarised in Table 2. The variables that were
assessed included gender, bundle branch morphol-
ogy, maximum tachycardia rate at presentation,
duration of initial tachycardia episode, number of
ventricular tachycardia episodes on initial 24-hour
ambulatory electrocardiogram recording, and date
on which the patient presented. No significant
difference was found between these two groups.
Outpatient clinical course
The outpatient clinical course is summarised in
Table 3. There were 115.5 patient-years of follow-
up entailed in this study. Mean total follow-up was
6.8 years with a range from 7 months to 10.7 years.
The mean number of patient visits was 7.7 with a
range from 3 to 20 visits.
Ventricular tachycardia resolved spontaneously in
all infants. The median age at the last ventricular
tachycardia episode was 60 days, with a range from
1 day to 2.29 years. The mean follow-up period
after ventricular tachycardia resolution was 41.1
months, with a range from 2.3 to 127 months. The
infant whose last ventricular tachycardia episode
was at 2.29 years had no ventricular tachycardia
episodes captured on 24-hour Holter monitor
studies performed between the ages of 9 months
and 2.29 years. No symptoms were reported in any
infants at follow-up.
The median duration of outpatient anti-arrhythmic
drug treatment was 223 days, with a range from 0
day to 8.5 years, following hospital discharge. One
infant who had no initial outpatient oral anti-
arrhythmic treatment was re-hospitalised at 4 months
of age to initiate propranolol treatment due to the
presence of ventricular tachycardia on 24-hour Holter
monitor.
No patient underwent radiofrequency catheter
ablation, received device therapy, underwent sur-
gery, or died. One infant had a transoesophogeal
electrophysiology study during which ventricular
tachycardia was induced following the administra-
tion of isoproterenol.
There was one adverse event that was attributed
to a medication side effect. A 27-month-old female
child received propranolol during an acute illness
during which the child had poor oral intake.
She subsequently suffered a hypoglycaemic seizure,
which was treated with parenteral glucose. The
child had no subsequent seizures.





medication (n5 9) p-value
Age at presentation (days) 24.46 63 286 79 NS
(0.694)
Sex
Male 10 3 NS*
Female 11 7 (0.353)
VT bundle branch morphology
Left 13 7 NS*
Right 3 1 (0.901)
Indeterminate 5 2
Maximum VT rate at presentation (bpm) 2176 26.9 2016 40.8 NS
(0.261)
Length of initial hospitalisation (days) 14.46 10.4 8.46 8.4 NS
(0.188)
Longest VT episode (bpm) 13716 3389 21.26 29.2 NS**
(0.063)
Number of VT episodes on initial Holter study 72456 20,302 11686 1937 NS**
(0.371)
Age at last VT (days) 1636 234 68.46 78.7 NS
(0.084)
Number of premature ventricular contractions
on initial Holter study
89906 33,005 37.36 25.3 NS
(0.147)
NS5 not significant; VT5 ventricular tachycardia
Student’s t-test used, unless indicated
*Fisher’s exact test
**Statistics calculated by Mann–Whitney test
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Survival analysis
To asses the effect of outpatient oral anti-arrhythmic
administration on the course of idiopathic ventri-
cular tachycardia, we constructed the Kaplan–Meier
survival curves for children who received outpatient
oral medication as well as a similar curve for those
children who received no outpatient medication.
Again, there were no complications or deaths in
those infants who received no outpatient medica-
tion. We compared the survival curves of these two
groups using the log-rank statistic. Figure 2 shows
the result of this analysis. The log-rank statistic was
1.94, yielding a p-value of 0.167. Thus, there was
no statistically significant difference between the
survival plots of those taking oral anti-arrhythmics
and those taking no anti-arrhythmic drugs.
Discussion
Idiopathic ventricular tachycardia in infants with
structurally normal heart is a rare disorder. We
performed a retrospective analysis of all cases of
idiopathic ventricular tachycardia in children under
the age of 1 year who presented to our institution
since 1987. We found that a distinct cohort of
infants without structural cardiac disease, prolonged
QT interval, or overt signs of cardiomyopathy had a
benign course with spontaneous resolution of their
tachycardia.
Previously, published series of idiopathic ventri-
cular tachycardia in children show findings similar
to ours.1–5,7,8,14 In general, the reports to date
suggest a favourable prognosis for idiopathic
ventricular tachycardia infants. Most recently,
Pfammatter and paul concluded that idiopathic
ventricular tachycardia carries a favourable prog-
nosis.6 Furthermore, these authors suggested chil-
dren with normal left ventricular function by
echocardiogram, who were asymptomatic, could be
followed without drug treatment.6 This study,
however, included heterogeneous populations of
children, ranging in age from the neonatal period
to 16 years old.
Although the majority of the reports shows a
benign prognosis, deaths have been reported in
children with ventricular tachycardia without struc-
tural cardiac disease. This discrepancy likely results
from discrepant patient populations. Fulton et al,3
report no deaths in their cohort, but cite reports of
nine deaths in previously reported cases of ventricular
tachycardia among children without structural cardiac
disease. Included in this latter group were infants with
myocarditis. Deal et al2 reported a 13% mortality in
their cohort. The infants in this study ranged from
6 to 21 years of age.2,7 Garson et al9,13 reported cases
of incessant ventricular tachycardia in infants arising
from hamartomas or Purkinje cell tumours. None of
our infants had such incessant tachycardia. Gillette10





treatment p-value Mean (s.d.) Range
Duration of Anti-arrhythmic therapy (days) Median 382 – – 3646 102 0–3135
Range:
102–3135
Length of follow-up (months) 101.26 266 36.426 26.5 NS (0.476) 82.66 225 7–1284
Number of visits 8.36 3.6 6.16 3.5 NS (0.129) 7.76 3.6 3–20
Median age at last VT episode (days) 157.26 230.0 72.36 82.5 NS (0.293) 60 1–836
Days observed VT free 1298.26 923.6 1055.96 777.9 NS (0.495) 12336 875 70–3810
VT5 ventricular tachycardia; NS5 not significant
Student’s t-test is used to determine significance
Figure 2.
Kaplan–Meier survival-type plot showing the number of days to
ventricular tachycardia resolution stratified by those receiving
outpatient anti-arrhythmic medications and those receiving no
outpatient anti-arrhythmic medication. Log-rank statistic shows no
statistical difference between survival plots (log-rank test5 1.735,
p5 0.1877).
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suggested that there was an infrequent progression
from neonatal ventricular tachycardia to such incessant
ventricular tachycardia caused by hamartomas. None
of the infants in our cohort showed such a progression.
This finding is consistent with those reported by Van
Hare and Stanger.8
The limitations of this study rest on its retro-
spective nature. Although we describe the largest
cohort of infants with ventricular tachycardia and
structurally normal heart, the number of cases
remains relatively small. Finally, the diagnosis of
ventricular tachycardia was based on non-invasive
tracings, instead of directly recording ventricular
electrograms within a laboratory setting.
We have shown that ventricular tachycardia in
an infant who has a structurally normal heart,
without symptoms of haemodynamic compromise
or alternate electrophysiologic diagnosis follows a
benign course. Ventricular tachycardia resolved in
all infants without the occurrence of life-threatening
events or death. We have further shown that there
was no difference in the clinical outcome or clinical
course between those infants who received out-
patient medication and those who received no
outpatient anti-arrhythmic therapy. All infants
had a resolution of their ventricular tachycardia,
regardless of whether or not they received out-
patient anti-arrhythmic drugs. This conclusion was
drawn after constructing the Kaplan–Meier survival
curves for the infants who received outpatient anti-
arrhythmic agents with those who received no such
outpatient medication. Statistical analysis showed
no significant differences between these groups
that might have led to a selection bias to one of
the two groups. Interestingly, the only infant with
significant morbidity was the one who suffered
hypoglycaemic seizures associated with propranolol
administration. Although indications for therapy
cannot be determined from this study, the lack of
symptoms or myocardial dysfunction suggests that
therapy may not be necessary in this narrowly
defined group of infants.
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